CDK4 and melanoma: Most importantly, the inhibition of CDK4/6 was nevertheless able to reverse, in all the evaluated MPM cell lines, the ‘immune resistance programme’ that promotes T cell exclusion and resistance to immunotherapy in melanoma [66] (Fig. 4D,E).